Download PDF
Z Geburtshilfe Neonatol 2001; 205(6): 231-235
DOI: 10.1055/s-2001-19055
FORTBILDUNG

Georg Thieme Verlag Stuttgart · New York

Die perinatale Therapie mit Glukokortikosteroiden: Zeit zum Umdenken[1]

Perinatal Glucocorticosteroid Therapy: Time for ReconsiderationP. Groneck
  • Neonatologie und pädiatrische Intensivmedizin, Kliniken der Stadt Köln, Kinderkrankenhaus, Köln
Further Information

Publication History

Publication Date:
17 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Glukokortikosteroide werden sowohl prä- als auch postnatal zur Senkung der pulmonalen Morbidität Frühgeborener eingesetzt. Ein einmaliger pränataler Steroidzyklus reduziert die Mortalität Frühgeborener sowie die Häufigkeit des Atemnotsyndroms und der Hirnblutung. Die Verabreichung repetitiver Behandlungszyklen kann jedoch möglicherweise einen ungünstigen Einfluss auf die Hirnentwicklung haben. Nachuntersuchungsstudien von Kindern mit mehrfachen pränatalen Steroidzyklen sind erforderlich. Die Art des verwendeten Steroids ist offenbar ebenfalls von Bedeutung für die zerebrale Morbidität von Frühgeborenen, die derzeitige Datenlage favorisiert Betamethason gegenüber Dexamethason. Postnatal werden Steroide zur Prophylaxe oder Therapie der bronchopulmonalen Dysplasie (BPD) verabreicht. Neuere Untersuchungen haben jedoch gezeigt, dass die Behandlung der BPD mit Dexamethason zu einer erhöhten Rate an Zerebralparesen führt. Die postnatale Behandlung der BPD mit Steroiden sollte auf lebensbedrohliche Situationen begrenzt werden.

Glucocorticosteroids are administered antenatally and postnatally to decrease pulmonary morbidity of preterm neonates. One course of antenatal corticosteroids decreases mortality, and the frequency of respiratory distress syndrome and intraventricular hemorrhage. However, multiple courses may be associated with impaired brain development. Follow-up studies are needed to assess long-term consequences. The use of betamethasone may be of advantage compared to dexamethasone. Postnatally, steroids are given to treat or prevent bronchopulmonary dysplasia (BPD). However, recent studies have shown that treatment with dexamethasone increases the rate of cerebral palsy in preterm infants. Postnatal treatment of BPD with steroids should be restricted to life-threatening situations.

Schlüsselwörter

Perinatale Steroidtherapie - Glukokortikoide - Dexamethason - Betamethason - bronchopulmonale Dysplasie

Key words

Perinatal corticosteroids - glucocorticosteroids - dexamethasone - betamethasone - bronchopulmonary dysplasia

1 Eingang: 7. 3. 2001
Angenommen nach Revision: 9. 4. 2001

Literatur

1 Eingang: 7. 3. 2001
Angenommen nach Revision: 9. 4. 2001

  • 01 Crowley  P A. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials 1972 to 1994.  Am J Obstet Gynecol. 1995;  83 483-494
    Google Scholar
  • 02 Sauerwald  A, Rath  W. Lungenreifetherapie mit Glukokortikoiden bei drohender Frühgeburt.  Z Geburtsh Neonatol. 2000;  204 203-209
    Google Scholar
  • 03 Ballard  P L, Granberg  P, Ballard  R A. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.  J Clin Invest. 1975;  56 1548-1554
    Google Scholar
  • 04 Whitelaw  A, Thoresen  M. Antenatal steroids and the developing brain.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F154-F157
    Google Scholar
  • 05 Barres  B A, Lazar  M A, Raff  M C. A novel role for thyroid hormone, glucocorticoids, and retinoic acid in timing oligodendrocyte development.  Development. 1994;  120 1097-1108
    Google Scholar
  • 06 Gumbinas  M, Oda  M, Huttenlocher  P. The effects of corticosteroids on myelination of the developing rat brain.  Biol Neonate. 1973;  22 355-366
    Google Scholar
  • 07 Carlos  R Q, Seidler  F J, Slotkin  T A. Fetal dexamethasone exposure alters macromolecular characteristics of rat brain development: A critical period for regionally selective alterations?.  Teratoloy. 1992;  46 45-59
    Google Scholar
  • 08 Slotkin  T A, Lappi  S E, McCook  E C, Tayyeb  M I, Eylers  J P, Seidler  F J. Glucocorticoids and the development of neuronal function: Effects of prenatal dexamethasone exposure on central noradrenergic activity.  Biol Neonate. 1992;  61 326-336
    Google Scholar
  • 09 Benesova  O, Pavlik  A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain.  Neuropharmacology. 1989;  28 89-97
    Google Scholar
  • 10 Cotterrell  M, Balazs  R, Johnson  A. Effects of corticosteroids on the biochemical maturation of rat brain: postnatal cell formation.  J Neurochem. 1972;  19 2151-2167
    Google Scholar
  • 11 Huang  W L, Beazley  L D, Quinlivan  J A, Evans  S F, Newnham  J P, Dunlop  S A. Effect of corticosteroids on brain growth in fetal sheep.  Obstet Gynecol. 1999;  94 213-218
    CrossrefPubMedGoogle Scholar
  • 12 Quinlivan  J A, Dunlop  S ASF, Newnham  J P, Evans  S F, Beazley  L D. Repeated, but not single maternal administration of corticosteroids delays myelination in the brain of fetal sheep.  Prenatal and Neonatal Medicine. 1999;  4 47-55
    PubMedGoogle Scholar
  • 13 French  N P, Hagan  R, Evans  S F, Godfrey  M, Newnham  J P. Repeated antenatal corticosteroids: Size at birth and subsequent development.  Am J Obstet Gynecol. 1999;  180 114-121
    PubMedGoogle Scholar
  • 14 Hack  M, Breslau  N, Weissman  B, Aram  D, Klein  N, Borawski  E. Effect of very low birth weight and subnormal head size on cognitive abilities at school age.  N Engl J Med. 1991;  325 231-237
    PubMedGoogle Scholar
  • 15 NIH Consensus Development Panel .Effects of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995 273: 413-417
    Google Scholar
  • 16 Mc Arthur  B A, Howie  R N, Dezoete  J A, Elkins  J. School progress and cognitive development of 6 year-old children whose mothers were treated antenatally with betamethasone.  Pediatrics. 1982;  70 99-105
    PubMedGoogle Scholar
  • 17 Doyle  L W, Ford  G W, Rickards  A L, Kelly  E A, Davis  N M, Callanan  C, Olinsky  A. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams.  Pediatrics. 2000;  106 e2
    CrossrefPubMedGoogle Scholar
  • 18 Dessens  A, Smolders-de Haas  H, Koppe  J G. Twenty-year follow-up of antenatal corticosteroid treatment.  Pediatrics. 2000;  105 e77
    CrossrefPubMedGoogle Scholar
  • 19 Rennie  J M, Wheater  M, Cole  T J. Antenatal steroid administration is associated with an improved chance of intact survival in preterm infants.  Eur J Pediatr. 1996;  155 576-579
    CrossrefPubMedGoogle Scholar
  • 20 Baud  O, Foix-Helias  L, Kaminski  M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants.  N Engl J Med. 1999;  341 1190-1196
    CrossrefPubMedGoogle Scholar
  • 21 Ewerbeck  H, Helwig  H. Treatment of idiopathic respiratory distress syndrome with large doses of corticoids.  Pediatrics. 1972;  49 467-468
    PubMedGoogle Scholar
  • 22 Baden  M, Bauer  C R, Colle  E, Klein  G, Taeusch  H W, Stern  L. A controlled trial of hydrocortsisone therapy in infants with RDS.  Pediatr. 1972;  50 526-534
    PubMedGoogle Scholar
  • 23 Mammel  M C, Green  T P, Johnson  D A, Thompson  T R. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia.  Lancet. 1983;  1 1356-1358
    PubMedGoogle Scholar
  • 24 Avery  G B, Fletcher  A B, Kaplan  M, Brudno  D S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.  Pediatrics. 1985;  75 106-111
    CrossrefPubMedGoogle Scholar
  • 25 Harkavy  K L, Scanlon  J W, Chowdhry  P K, Grylack  L J. Dexamethasone therapy for chronic lung disease in ventilator and oxygen-dependent infants: a controlled trial.  J Pediatr. 1989;  115 979-993
    PubMedGoogle Scholar
  • 26 Cummings  J J, D'Eugenio  D B, Gross  S J. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia.  N Engl J Med. 1989;  320 1505-1510
    PubMedGoogle Scholar
  • 27 Halliday  H L. Clinical trials of postnatal corticosteroids: inhaled and systemic.  Biol Neonate. 1999;  76 Suppl 29-40
    CrossrefPubMedGoogle Scholar
  • 28 Groneck  P, Soditt  V, Bläker  F. Klinische Auswirkungen der Dexamethasontherapie bei Frühgeborenen mit hohem Risiko für eine bronchopulmonale Dysplasie.  Monatsschr Kinderheilkd. 1994;  142 279-284
    PubMedGoogle Scholar
  • 29 Groneck  P, Reuss  D, Götze-Speer  B, Speer  C P. Effects of dexamethasone on chemotatic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.  J Pediatr. 1993;  122 938-944
    PubMedGoogle Scholar
  • 30 Ng  P C. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.  Arch Dis Childh. 1993;  68 330-336
    PubMedGoogle Scholar
  • 31 Shinwell  E S, Karplus  M, Zamora  E et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.  Arch Dis Childh Fetal Neonatal Ed. 1996;  74 F33-F37
    PubMedGoogle Scholar
  • 32 Shinwell  E S, Karplus  M, Reich  D, Weintraub  Z, Blazer  S, Bader  D et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.  Arch Dis Child Fetal Neonatal Ed. 2000;  83 F177-F181
    PubMedGoogle Scholar
  • 33 Yeh  T F, Lin  Y J, Huang  C C, Chen  Y J, Lin  C H, Lin  H C, Hsieh  W S, Lien  Y J. Early dexamethasone therapy in preterm infants: a follow up study.  Pediatrics. 1998;  101 E7
    PubMedGoogle Scholar
  • 34 O'Shea  T M, Kothadia  K L, Klinepeter  K L, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.  Pediatrics. 1999;  104 15-21
    CrossrefPubMedGoogle Scholar
  • 35 Sapolsky  R M. Corticosteroids and hippocampal damage.  Trends Neurosci. 1987;  10 346-349
    CrossrefPubMedGoogle Scholar
  • 36 Wooley  C, Gould  E, McEwen  B. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons.  Brain Res. 1990;  531 225
    CrossrefPubMedGoogle Scholar
  • 37 Murphy  B P, Inder  T E, Hüppi  P, Warfield  S, Zientara  G P, Kikinis  L, Jolesz  F A, Volpe  J J. Impaired cerebral cortical grey matter growth after treatment with dexamethasone for neonatal chronic lung disease.  Pediatrics. 2001;  107 217-221
    CrossrefPubMedGoogle Scholar
  • 38 Halliday  H L, Ehrenkranz  R A. Early (< 96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001146
    PubMedGoogle Scholar
  • 39 Halliday  H L, Ehrenkranz  R A. Moderately early (7 - 14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001144
    PubMedGoogle Scholar
  • 40 Halliday  H L, Ehrenkranz  R A. Delayed (> 3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants.  Cochrane Database Syst Rev. 2000;  (2) pCD001145
    PubMedGoogle Scholar
  • 41 Baud  O, Zupan  V, Lacaze-Masmontail  T, Dehan  M. Neurological adverse effects of early postnatal dexamethasone in very preterm infants.  Arch Dis Childh Fetal Neonatal Ed. 1999;  80 F159
    PubMedGoogle Scholar
  • 42 André  P, Thebaud  B, Odievre  M H, Razafimahefa  H, Zupan  V, Dehan  M, Lacaze-Masmonteil  T. Methylprednisolon, an alternative to dexamethasone in very preterm infants at risk of chronic lung disease.  Intensive Care Med. 2000;  26 1496-1500
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. Peter Groneck

Leitender Arzt Neonatologie und pädiatrische Intensivmedizin
Kliniken der Stadt Köln
Kinderkrankenhaus

Amsterdamer Str. 59

50735 Köln

      >